Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Zynlonta First FDA-Approved CD19-Targeted Therapy for Large B-Cell Lymphoma

June 2021 Vol 7 No 3

In April 2021, the FDA accelerated the approval of Zynlonta (loncastuximab tesirine-lpyl; from ADC Therapeutics SA), an intravenous CD19-directed antibody and alkylating drug conjugate, for the treatment of relapsed (coming back) or refractory large B-cell lymphoma, including unspecified diffuse large B-cell lymphoma (DLBCL), DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma, in adults who have received 2 or more systemic therapies.

Zynlonta is the first and only CD19-targeted antibody–drug conjugate that is approved as a single-drug treatment for patients with relapsed or refractory large B-cell lymphoma.

“There is a significant unmet need for treatment options for patients with relapsed/refractory DLBCL, including those who have been heavily pretreated and have difficult-to-treat disease. Single-agent Zynlonta demonstrated clinically important outcomes in the pivotal LOTIS-2 study across several disease subtypes,” said Paolo F. Caimi, MD, University Hospitals Cleveland Medical Center and Case Comprehensive Cancer Center, Case Western Reserve University. He added that this included patients who were eligible or ineligible for a transplant, as well as patients who already had a transplant.

The FDA approval of Zynlonta was based on the LOTIS-2 clinical trial that included 145 adults with relapsed or refractory DLBCL or high-grade B-cell lymphoma who had received 2 or more systemic regimens.

Overall, 48.3% of the patients had a response to treatment with Zynlonta, of which 24.1% were complete responses (no sign of cancer). The average duration of response was 10.3 months.

The most common side effects reported with Zynlonta were low platelets, neutropenia, anemia, hyperglycemia, fatigue, hypoalbuminemia, rash, edema, nausea, and musculoskeletal pain.

Recommended For You